Axonics Modulation Technologies (Nasdaq:AXNX) reported first-quarter financial results that topped analysts’ consensus forecast. The Irvine, California–based sacral neuromodulation technology developer posted losses of $22.7 million, or 50¢ per share, on sales of $48.4 million for the three months ended March 31, 2022, for a slight bottom-line loss of just over $150,000 year-over-year on sales growth […]
Neurological
Welcome to MassDevice's Neurological Hub, your resource for the latest news in the neurological device space. Stay informed about the innovations and business news shaping the neurological industry.
🧠 Narrow your focus with these categories:
Neuromodulation/Neurostimulation | Bioelectronic Medicine | Pain Management | Brain-Computer Interfaces
Here are the top neurological device features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ 7 brain-computer interface companies you need to know
+ Brain breakthroughs: Aprinoia Therapeutics’ harnesses AI and strategic partnerships to propel neurodegenerative disease research
+ Natalizumab and PML: The complex dance of benefit and risk for MS
Latest Neurological News
Digital therapeutics open up new opportunities in medicine
A wide range of companies are aiming to make waves through digital therapeutic offerings, and each is doing things differently. “We are seeing tremendous momentum for the DTx industry, with more and more products coming to market and gaining commercial coverage and recent signals from the White House and Congress demonstrating their interest and recognition […]
How DeepWell is developing video games as tools for treating medical conditions
Imagine playing a video game where you are a wizard fighting for good in a magical realm. You must master control of your mind and body to increase your powers and abilities, creating a forcefield shielding you from enemies and strengthening your counterattack. In these moments of high anxiety, more control makes you more powerful, […]
Stevanato Group, Bexson expand partnership for wearable drug delivery device
Stevanato Group and Bexson Biomedical announced today that they agreed to expand their drug delivery collaboration. Under the agreement, Bexson has access to the use of a customized version of Stevanato’s SG EZ-be Pod wearable delivery system so it can develop new therapeutics for treating an array of mental health conditions, including treatment-resistant depression and post-traumatic stress disorder […]
Ear-puffing device for migraine treatment wins FDA breakthrough designation
A handheld device that treats migraine attacks with puffs of air in a patient’s ears has been designated a breakthrough device by the FDA. Tempe, Arizona-based Nocira said it is the first company to announce breakthrough device designation for treating migraine attacks in both chronic and non-chronic migraine patients ages 18 and up. The device […]
Medtronic warns on some Percept neurostimulators
Medtronic (NYSE:MDT) has issued an urgent field safety notice in Europe regarding its Percept PC implantable neurostimulator (INS). The letter informs users that, in rare instances (0.044%), the Percept PC INS Model B35200 can’t communicate with the clinician programmer and/or the patient programmer system (HH90 Handset and TM91 Communicator). According to the safety notice, in […]
NeuroMetrix revenues rise in Q1
NeuroMetrix (Nasdaq:NURO) shares dipped today on first-quarter results that saw losses despite year-over-year revenue growth. The Woburn, Massachusetts–based company posted losses of $958,562, or 14¢ per share, on sales of $2.3 million for the three months ended March 31, 2022, for a bottom-line slide deeper into the red on sales growth of 6.8%. NeuroMetrix’s biggest […]
Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation
Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas — and the central nervous system. The company’s Trudhesa nasal spray for treating migraine in adults received […]
Masimo says study supports using SedLine brain monitoring during cardiac surgery
Masimo (Nasdaq:MASI) announced today that a retrospective study backed the use of its SedLine brain function monitoring system. Irvine, California-based Masimo’s study investigated the impact of anesthesia during cardiac surgery guided by SedLine monitoring. The company published the findings in the Journal of Cardiothoracic and Vascular Anesthesia. According to a news release, Dr. André Denault and […]
Abbott launches upgraded digital health app for neurostimulation
Abbott (NYSE:ABT) announced today that it launched an upgraded version of its NeuroSphere myPath digital health app. The Abbott Park, Illinois-based company designed the upgraded app with enhanced functionality to help doctors more closely track their patients as they trial Abbott neurostimulation devices to address their chronic pain. According to a news release, Abbott’s digital […]
Abbott beats The Street in Q1 as COVID-19 testing continues to drive revenue growth
Abbott (NYSE:ABT) shares are up today on first-quarter results ahead of the consensus forecast, with the company sticking by its full-year adjusted EPS projection. The Abbott Park, Illinois-based company posted profits of $2.4 billion, or $1.37 per share, on sales of $11.9 billion for the three months ended March 31, 2022, for a 36.5% bottom-line […]